

# Novel Coronavirus Disease (COVID-19)

## Situation Update Report – 95



November 24, 2021

### HIGHLIGHTS

- MoHFW releases NFHS-5 Phase II Findings ([Link](#))
- India and Asian Development Bank sign \$300 million loan to improve primary health care in India ([Link](#))
- Union Minister of Health urges States to rope in various stakeholders including NGOs, Faith-based Organizations, religious leaders, and community influencers to ensure 100% COVID-19 vaccination ([Link](#))
- More than 131 Crore vaccine doses provided to States/UTs ([Link](#))



### INDIA SITUATION

- As of 23 November, India reported a total of 34,526,480 confirmed cases. In the past 24 hours, 7,579 confirmed cases have been reported, this is the lowest single day cases after second wave. Currently, India reports 49 cases per million per week (7DMA: 17-24 November).



### COVID-19: STATUS ACROSS STATES

- Maharashtra is still leading with highest number of cases (more than six million); followed by Kerala more than five million cases, and Karnataka, Tamil Nadu and Andhra Pradesh (more than two million cases each). States with more than one million cases reported are Uttar Pradesh, West Bengal, Delhi, Odisha and Chhattisgarh.
- Top five states, namely, Maharashtra, Kerala, Karnataka, Tamil Nadu, and Andhra Pradesh contribute 57% of total cases. During last seven days 70,079 cases were reported in the country with Kerala reporting highest number of cases (39,083, 56% of total cases) followed by Maharashtra (5,545) and West Bengal (5,485)
- In the last week (17- 23 November), as compared to previous week (10-16 November), 14 States/ UTs have recorded a rise in the number new cases and 13 States/UTs have reported slight increase in the number of deaths; however, the absolute numbers are very less.
- On warning level indicators of cases per million per week, % change in weekly cases and test positivity rate (7DMA), there are 36 districts in different states with warning level-4.



# Novel Coronavirus Disease (COVID-19)

## Situation Update Report – 95

November 24, 2021

### WHO GLOBAL UPDATE

- WHO's COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) has finalized a licensing agreement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology. The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine, details [here](#)
- WHO issued updated [guidelines](#) on the management of multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C). MIS-C is a rare but serious condition where children with COVID-19 develop inflammation affecting different organs of the body, details [here](#)
- WHO's Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) held its first meeting; the group agreed to meet frequently and focus urgently on advising on the overarching framework to study the emergence of novel pathogens, as well as to rapidly undertake an assessment of the current understanding of the origins of SARS-CoV-2, details [here](#)
- WHO with support of the Strategic Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines Working Group, is reviewing the emerging evidence on the need for and timing of vaccinating children and adolescents with the currently available COVID-19 vaccines which have received Emergency Use Listing (EUL), details [here](#)

### WHO COUNTRY UPDATE

#### Coordination

- WHO field staff continue to participate in state and district task force meetings on current response, preparations for any possible future surges, vaccination; chaired by Chief Ministers, Health Ministers, Health Secretaries and MDs- NHM.

#### COVID-19 vaccination

- Technical oversight during vaccination is provided by WHO teams at district and state levels.
- WHO field offices are supporting monitoring of vaccination sessions across the country and continue to provide surge support for training, microplanning and monitoring.
- "Har Ghar Dastak Abhiyan" for COVID-19 vaccination was supported in **Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, Chhattisgarh, Maharashtra, Bihar, Jharkhand, Punjab, and Haryana**
- Providing technical support in strengthening the capacity of personnel deployed at call centres for COVID-19 vaccination in **Delhi**
- Participated in Effective Vaccine Management (EVM) training in **Chhattisgarh**

#### Surveillance, Contact Tracing and Containment

- WHO Country office provided technical support and supportive supervision to monitor contact tracing; identify containment zones for COVID-19 containment activities in **Uttar Pradesh**.
- Assisting a house-to-house survey for ILI/SARI in **Uttar Pradesh**.

#### Capacity building

- Supporting training of medical officers on Routine Immunization and essential immunization services in **Delhi, Andhra Pradesh, Karnataka, and Telangana**.

#### Support in ensuring delivery of Essential Health Services

- Providing technical support to strengthen VPD surveillance and immunization in **Delhi, Jammu & Kashmir, Andhra Pradesh, and Tamil Nadu**
- Supporting in strengthening and streamlining AEFI surveillance for **Maharashtra, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, and Telangana**.
- Improving coverage of Hepatitis B vaccine birth dose in **Maharashtra**.

# Novel Coronavirus Disease (COVID-19)


## Situation Update Report – 95

November 24, 2021

As of 23 November 2021, India has tested more than 615 million samples. Tests include both, RTPCR and Rapid Antigen. India's current test positivity rate (7DMA) is 0.94%.


### Testing - National Level

**61,52,02,480 \***  
Cumulative Tests



India continued to drive COVID-19 vaccinations among various age group with preconditions, details [here](#).

Cumulative Coverage Report of COVID-19 vaccination (as on 23 November 2021, 07:00 AM)

 VACCINATION	Beneficiaries vaccinated		
	1 <sup>st</sup> Dose	2 <sup>nd</sup> Dose	Total Doses
	76,83,97,360	40,79,76,139	1,17,63,73,499
	23,22,747 in last 24 Hours	48,69,407 in last 24 hours	71,92,154 in last 24 Hours

## IMPORTANT GUIDELINES/TECHNICAL PUBLICATIONS

- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing ([LINK](#)); Annexes ([LINK](#))
- Interim recommendations for use of Moderna mRNA-1273 vaccine for COVID-19 ([LINK](#)); Annexes ([LINK](#))
- Assessment of HIV testing services and antiretroviral therapy service disruptions in the context of COVID-19: lessons learned and way forward in sub-Saharan Africa ([LINK](#))
- Living guidance for clinical management of COVID-19 ([LINK](#))
- WHO third global infodemic management conference: whole-of-society challenges and approaches to respond to infodemics: Technical document ([LINK](#))
- MoHFW's Guidelines for provision of Family Planning services during and post COVID-19 Pandemic ([LINK](#))

Click to access latest publications from [WHO](#) and [MoHFW](#)

## FOR MORE INFORMATION CONTACT

In case of any queries on COVID-19, call +91-11-23978046 or 1075 (Toll-free). State Helpline [here](#).  
WHO Country Office for India | Telephone number: [+91-11-66564800](#) | Email: [wrindia@who.int](mailto:wrindia@who.int)